http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017203009-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8bb11fc5f69b5f246d66178e6dde691a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7007 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 2017-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d64d9d31ca2dc49a62252baed7f8741 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7f05a7f0b5c31f20dd8a474692b7980 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffeef64b856ef5c51c71878f01f31b93 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad61d85bcddca07e63016a6302b310c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bb31b7f3e32a2b3d5ac3b8da55e5c64a |
| publicationDate | 2017-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AU-2017203009-A1 |
| titleOfInvention | Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer |
| abstract | Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, particularly diethylstilbestrol and pharmaceutically acceptable salts thereof to patients through insertion into the mouth of patient and methods for 5 administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract. In particular the present invention relates to a pharmaceutical composition comprising: a water soluble matrix comprising an effective amount of a pharmaceutically active agent and an absorption enhancer having an HLB of about 8 to o about 16; wherein the pharmaceutically active agent is selected from the group consisting of diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol; and wherein the absorption enhancer is one or more sucrose fatty acid esters selected from the group consisting of sucrose stearate, sucrose palmitate, sucrose laurate and sucrose oleate. The present invention further relates to a method for 5 treating prostate or breast cancer in a patient comprising administering an oral unit dosage form as a water soluble matrix to the oral mucosal membranes of the mouth of a patient, which matrix contains, dispersed therein, a pharmaceutical agent selected from the group consisting of diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol, said pharmaceutical agent being present in said matrix in an amount 2o effective for treating said prostate or breast cancer, said matrix is composed of an absorption enhancer being one or more sucrose fatty acid esters having an HLB of about 8 to 16, and selected from the group consisting of sucrose stearate, sucrose palmitate, sucrose laurate and sucrose oleate. Finally the present invention relates to the use of diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol for the manufacture of a medicament for treatment of prostate or breast cancer in a patient, comprising administering an oral unit dosage form as a water soluble matrix to the oral mucosal membranes of the mouth of a patient, which matrix contains, dispersed therein, diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol and 5 wherein the diethylstilbestrol and pharmaceutically acceptable salts of diethylstilbestrol are present in said matrix in an amount effective for treating said prostate or breast cancer, said matrix is composed of an absorption enhancer being one or more sucrose fatty acid esters having an HLB of about 8 to 16 and selected from the group consisting of sucrose stearate, sucrose palmitate, sucrose laurate and sucrose oleate. |
| priorityDate | 2011-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 85.